Bausch Health (BHC)
(Delayed Data from NYSE)
$5.63 USD
-0.47 (-7.70%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.62 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Bausch Health (BHC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.43 | $13.00 | $7.00 | 54.59% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Bausch Health comes to $9.43. The forecasts range from a low of $7.00 to a high of $13.00. The average price target represents an increase of 54.59% from the last closing price of $6.10.
Analyst Price Targets (7 )
Broker Rating
Bausch Health currently has an average brokerage recommendation (ABR) of 2.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.83 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, one is Strong Buy, representing 14.29% of all recommendations. A month ago, Strong Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BHC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 4 | 4 | 4 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.86 | 2.86 | 2.83 | 2.83 | 2.83 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/2/2024 | Piper Sandler | David Amsellem | Strong Sell | Strong Sell |
7/10/2024 | Raymond James | Gary Nachman | Not Available | Hold |
5/3/2024 | Truist Securities | Leszek Sulewski | Hold | Hold |
4/5/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Michael Nedelcovych | Hold | Hold |
2/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.86 |
ABR (Last week) | 2.86 |
# of Recs in ABR | 7 |
Average Target Price | $9.29 |
LT Growth Rate | NA |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 71 of 253 |
Current Quarter EPS Est: | 1.01 |